European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"The value of targeting CXCR4 with ⁶⁸Ga-Pentixafor PET/MRI for Cushing's disease: a retrospective cohort study.","authors":"Boyuan Yao, Yuyu Liu, Yanfei Wu, Mengxu Cui, Zengyi Ma, Nidan Qiao, Shuo Zhang, Yi Wang, Fang Xie, Yihui Guan, Zhenwei Yao, Zhaoyun Zhang, Hongying Ye, Yongfei Wang, Yao Zhao, Yue Wu, Qilin Zhang","doi":"10.1007/s00259-026-07821-6","DOIUrl":"10.1007/s00259-026-07821-6","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"4199-4210"},"PeriodicalIF":7.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146224979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Lesion-adaptive Segmentation Approach for Tumor Delineation on FDG PET/CT in Diffuse Large B-cell Lymphoma Patients.","authors":"Gerben J C Zwezerijnen, Martijn W Heymans, Danielle van Assema, Michael D A van Elk, Jakoba J Eertink, Patricia C Spa, Sanne E Wiegers, Pieternella J Lugtenburg, Yvonne W S Jauw, Otto S Hoekstra, Josée M Zijlstra, Ronald Boellaard","doi":"10.1007/s00259-026-07768-8","DOIUrl":"10.1007/s00259-026-07768-8","url":null,"abstract":"<p><strong>Purpose: </strong>SUV4.0-based thresholding is widely used for baseline [¹⁸F]FDG PET-based metabolic tumor volume (MTV) assessment in diffuse large B-cell lymphoma (DLBCL), but its suitability at interim and end-of-treatment (EoT) PET, when residual uptake is heterogeneous and tumor-to-background contrast is lower, is uncertain. We aimed to define a lesion-adaptive decision rule approach for selecting the optimal segmentation method based on lesion-level features and treatment phase and, exploratorily, to compare its performance with ML-based selection models.</p><p><strong>Methods: </strong>A total of 598 lesions from 33 DLBCL patients (HOVON-84 trial) were segmented at baseline, interim, and EoT [¹⁸F]FDG PET/CT using six semi-automated methods: SUV2.5, SUV4.0, 41%max, A50peak, MV2, and MV3. Segmentation quality was independently rated for each lesion by two observers (scale 1-5; 3 = preferred), with adjudication by a third reviewer. The influence of lesional SUVpeak, tumor-to-background ratio (TBRpeak), background uptake (SUVbg), treatment phase, and location on segmentation quality was assessed. Over six million rule-based combinations of key features were evaluated to derive a lesion-adaptive decision rule for preferred method selection. Exploratorily, ML classifiers were trained and compared with the decision-rule strategy.</p><p><strong>Results: </strong>Segmentation quality varied across lesions and methods. SUVpeak, TBRpeak, and SUVbg were key predictors of method performance. The final lesion-adaptive rule, applying SUV4.0 if SUVpeak > 8, MV3 if SUVbg > 0.8, and otherwise MV2, achieved a lesion-wise accuracy of 0.82 for preferred method selection, matching the best-performing ML models. Versus SUV4.0 alone (benchmark), the Decision Rule improved lesion-level MTV agreement with the reference (ρ = 0.85 vs. 0.82 vs. best ML ρ = 0.81) and reduced the proportion of lesions with > 10% MTV deviation (46.2% vs. 63.5%; best ML 50.2%). Total-MTV agreements with the reference were uniformly high across all strategies (all ρ ≥ 0.94), with modest gains for the decision rule at interim and EoT PET.</p><p><strong>Conclusion: </strong>A straightforward decision-rule approach using SUVpeak and SUVbg successfully selects the preferred method for individual DLBCL lesions across treatment phases and matches ML performance with greater simplicity and clinical applicability. Although supervision remains necessary, this approach helps address the current gap in segmentation methodology for interim and EoT PET, where SUV4.0 may not always be appropriate.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"4175-4185"},"PeriodicalIF":7.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13121395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146194247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of carbon-ion radiotherapy on tumor hypoxia detected by ¹⁸F-FMISO PET/CT in locally advanced non-small cell lung cancer.","authors":"Jian Chen, Jingyi Cheng, Ningyi Ma, Jingfang Mao, Kai-Liang Wu, Guo-Liang Jiang","doi":"10.1007/s00259-025-07702-4","DOIUrl":"10.1007/s00259-025-07702-4","url":null,"abstract":"<p><strong>Purpose: </strong>The study aimed to assess the impact of carbon-ion radiotherapy (CIRT) on intratumoral hypoxia in patients with locally advanced non-small cell lung cancer (LA-NSCLC) and the predictive value of ¹⁸F-fluoromisonidazole (FMISO) and ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT).</p><p><strong>Methods: </strong>We retrospectively analyzed patients with stage IIB-IIIC NSCLC treated with CIRT who underwent baseline ¹⁸F-FMISO and ¹⁸F-FDG PET/CT and post-CIRT ¹⁸F-FMISO PET/CT. Regions of interest (ROIs) with a diameter ≥ 3 cm were analyzed. An ROI was defined as hypoxia with a tumor-to-muscle ratio (TMR) ≥ 1.4 on ¹⁸F-FMISO PET/CT. Survival outcomes were evaluated using Kaplan-Meier curves, and group comparisons were performed using Log-rank test.</p><p><strong>Results: </strong>Thirty-seven eligible patients with 42 ROIs were included. Significant reductions in all ¹⁸F-FMISO parameters were observed after CIRT. ROIs with or without pre-CIRT hypoxia achieved similar local control (LC, with vs. without hypoxia: 75.5% vs. 85.5%, p = 0.799). The overlap ratios of hypoxic volumes between pre-/post-CIRT were 58.13%-81.34%. The combination of ¹⁸F-FDG uptake and post-CIRT hypoxia status demonstrated the strongest predictive value for LC (high vs. low uptake: 46.8% vs. 95.8%, p = 0.0004) with the highest area under the receiver operating characteristic curve (0.783, p = 0.01) among all evaluated combinations.</p><p><strong>Conclusion: </strong>Tumor hypoxia detected by ¹⁸F-FMISO PET/CT was significantly decreased after CIRT in patients with LA-NSCLC. Similar LC was achieved in patients with or without pre-CIRT hypoxia, while post-CIRT hypoxia clearance resulted in a non-significant trend toward improved LC. Combining ¹⁸F-FMISO and ¹⁸F-FDG PET/CT might provide enhanced prognostic value. Further investigation is warranted to explore individualized CIRT dose painting strategies guided by multi-tracer PET/CT imaging.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"3849-3861"},"PeriodicalIF":7.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13121404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146003080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic parameters and detection of cardiac amyloidosis with hybrid ¹⁸F-Florbetaben-PET/MRI: an exploratory observational study.","authors":"Lukas Kessler, Wibke Tonscheidt, Kai Nassenstein, Stephan Settelmeier, Alexander Carpinteiro, H Christian Reinhardt, Tim Hagenacker, Lale Umutlu, Christoph Kleinschnitz, Simon Wernhart, Lars Michel, Michal K Chodyla, Benedikt M Schaarschmidt, Thomas-Wilfried Schlosser, Wolfgang P Fendler, Francesco Barbato, Maria Papathanasiou, Christoph Rischpler, Ken Herrmann, Tienush Rassaf, David Kersting","doi":"10.1007/s00259-025-07733-x","DOIUrl":"10.1007/s00259-025-07733-x","url":null,"abstract":"<p><strong>Purpose: </strong>Positron emission tomography (PET) with amyloid-binding tracers was shown to have high sensitivity for the detection of both transthyretin (ATTR) and light-chain (AL) cardiac amyloidosis (CA). Recent studies describe prognostic value of imaging biomarkers from bone scintigraphy and ¹⁸F-Florbetapir. The aim of this study was to evaluate the value of imaging biomarkers from ¹⁸F-Florbetaben PET, cardiac magnetic resonance (CMR), and echocardiography imaging for prediction of major adverse cardiac events (MACE) in comparison to serum biomarkers in patients with different types of CA.</p><p><strong>Methods: </strong>Patients who underwent cardiac ¹⁸F-Florbetaben PET/MRI were prospectively enrolled and received clinical follow-up for up to 36 months and MACE were reported (NCT07154381). Scans were reported by two blinded, nuclear medicine physicians. Imaging biomarkers including average retention index (RI), T1 mapping/ extracellular volume (ECV) and serological markers were estimated and their association with MACE free survival was analyzed.</p><p><strong>Results: </strong>Twenty-one patients with confirmed CA were enrolled. MACEs were reported in 14 of 21 patients (66.7%). Higher average RI was the only imaging biomarker that was a significant predictor for MACE in uni- and multivariate analysis (HR = 4.02, 95%CI: 1.25-12.9, p < 0.05). N-terminal pro-B-type natriuretic peptide (NT-proBNP) was a significant predictor in uni- but not in multivariate analysis. Patients with AL-CA showed a higher rate of MACE than patients with other subtypes.</p><p><strong>Conclusion: </strong>Integrated ¹⁸F-Florbetaben PET/MR allows diagnosis, subtype differentiation and outcome predication of CA. The average RI was the only significant and independent prognostic imaging biomarker of MACE. Future prospective studies are warranted to investigate benefits for patient management and risk assessment in larger cohorts.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"3973-3984"},"PeriodicalIF":7.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13121523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness of [¹¹C]Choline PET/CT as first-line imaging in primary hyperparathyroidism.","authors":"H M Schouw, J Melis, J W Lutterop, H H Boersma, M E Noltes, C S van der Hilst, M I Bonnema, A P A Appelman, W T Zandee, S Kruijff, K M Vermeulen, A H Brouwers","doi":"10.1007/s00259-025-07746-6","DOIUrl":"10.1007/s00259-025-07746-6","url":null,"abstract":"<p><strong>Purpose: </strong>We performed a cost-utility analysis, using prospectively gathered trial data, comparing two imaging strategies for localizing parathyroid adenomas in primary hyperparathyroidism (pHPT) to determine the most cost-effective approach. Additionally, we provide customizable open-source R-script enabling other centres to identify their optimal imaging strategy based on local diagnostic accuracy and cost data.</p><p><strong>Methods: </strong>An evaluation of the diagnostic accuracy was performed for five imaging modalities: first-line cervical ultrasound (cUS) and [^99mTc]Tc-methoxy isobutyl isonitrile-single-photon-emission-computed- tomography/computed-tomography (MIBI SPECT/CT), and second-line [¹¹C]choline positron-emitting-tomography/CT (PET/CT), [¹¹C]methionine PET/CT, and 4 dimensional (4D)-CT. A decision-tree-model, constructed in R-studio, compared two diagnostic pathways: (1) The comparator pathway: a stepwise approach starting with cUS and MIBI SPECT/CT escalating to one of three second-line imaging modalities if needed, and (2) use of only one second-line imaging. Costs and quality-adjusted life years (QALYs) were evaluated across pathways, and cost-utility ratios (€/QALY) were calculated for a centre specific perspective with a 24-year time horizon based on life expectancy. In addition, to test the joint parameter uncertainty of the model, a probabilistic Monte-Carlo analysis was performed. One- and two-way sensitivity analyses were conducted to assess model robustness.</p><p><strong>Results: </strong>[¹¹C]choline PET/CT had a total costs of €10,394 and a QALY gain of 16.66. In contrast, the current standard, cUS + MIBI SPECT/CT with, when necessary, second-line imaging, costs €10,907 and yields 16.63 QALYs. The incremental cost-utility ratio (ICUR) for [¹¹C]choline PET/CT was -€18,846/QALY, indicating dominance with lower cost and greater effectiveness. Sensitivity analyses showed that cost-effectiveness was most sensitive to variations in costs of [¹¹C]choline PET/CT.</p><p><strong>Conclusion: </strong>This centre-specific model supports first-line [¹¹C]choline PET/CT as a cost-effective first-line strategy for localization of parathyroid adenomas, depending on [¹¹C]choline PET/CT costs. Additionally, the provided cost-utility model, enables other centres to determine their optimal imaging strategy.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"4186-4198"},"PeriodicalIF":7.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13121269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146141426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical research analysis of [²²⁵Ac]Ac-PSMA-617 therapy for [¹⁷⁷Lu]Lu-PSMA-refractory metastatic castration-resistant prostate cancer.","authors":"Zijuan Rao, Jiao Ma, Yangqing Jiangchu, Weiyu Yang, Fengyu Zhang, Meiling Hu, Chunyin Zhang, Yue Chen","doi":"10.1007/s00259-026-07778-6","DOIUrl":"10.1007/s00259-026-07778-6","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this evaluation was to identify the safety and efficacy for [²²⁵Ac]Ac-labeled prostate-specific membrane antigen-617 therapy in a retrospectively analyzed group of patients after [¹⁷⁷Lu]Lu-PSMA therapy.</p><p><strong>Methods: </strong>Metastatic castration-resistant prostate cancer patients after [¹⁷⁷Lu]Lu-PSMA were selected for treatment with 1 ~ 5 cycles of [²²⁵Ac]Ac-PSMA-617. Prostate-specific antigen and blood cell count were measured at the 2nd, 4th, and 8th week after treatment. [⁶⁸Ga]Ga-PSMA-11 PET/CT was used for baseline staging and imaging follow-up at the 2nd month. Safety was assessed according to the Common Terminology Criteria for Adverse Events version 5.0.</p><p><strong>Results: </strong>Eighteen patients were treated per protocol with a mean activity of 6.1 MBq in each cycle. 72.22% had a PSA decline at any degree, 55.56% had a PSA decline at more than 50%, and 38.89% had a PSA decline at more than 80%. According to PSMA PET progression criteria, disease control was achieved in 38.89% of the patients. The median progression-free survival under [²²⁵Ac]Ac-PSMA-617 after [¹⁷⁷Lu]Lu-PSMA therapy was 4 mo; the median overall survival was 17 mo. Any decline in PSA, a decline in PSA of ≥ 50%, prior treatment with at least 2 cycles and at least 3 cycles of [¹⁷⁷Lu]Lu-PSMA were all significantly associated with PFS. The median PFS was significantly longer for patients receiving ≥ 2 cycles of [¹⁷⁷Lu]Lu-PSMA therapy (4.8 mo, 95% CI: 3.7-5.9) compared to those receiving only 1 cycle (2.4 mo, 95% CI: 1.6-3.2). Median PFS was 5.3 mo (95% CI: 4.0-6.5) with ≥ 3 cycles of [¹⁷⁷Lu]Lu-PSMA therapy, compared to 3 mo (95% CI: 2.0-4.0) in those receiving < 3 cycles.Toxic reactions and adverse effects were mostly grade I ~ III and anemia is the most common hematological toxic reaction. The change in hemoglobin levels before and after [²²⁵Ac]Ac-PSMA treatment was statistically significant (p = 0.006). All patients experienced xerostomia to varying degrees.</p><p><strong>Conclusion: </strong>For metastatic castration-resistant prostate cancer patients intolerant or unresponsive to [¹⁷⁷Lu]Lu-PSMA treatment, [²²⁵Ac]Ac-PSMA-617 demonstrated significant and safe antitumor effects with relatively low treatment-related toxicity.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"3598-3606"},"PeriodicalIF":7.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146141111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From uniform to heterogeneous dose models: connecting cellular and tumor absorbed dose-response for [¹⁷⁷Lu]Lu-DOTATATE and [¹⁶¹Tb]Tb-DOTATATE.","authors":"Kaat Spoormans, Lara Struelens, Michel Koole, Melissa Crabbé","doi":"10.1007/s00259-026-07770-0","DOIUrl":"10.1007/s00259-026-07770-0","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"3809-3816"},"PeriodicalIF":7.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146141457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CXCR4-targeted PET/CT with [¹⁸F]AlF-NOTA-QHY-04 in primary central nervous system lymphoma: a prospective comparison with MRI and [¹⁸F]FDG PET/CT.","authors":"Yizhen Pang, Lijie Xing, Jingru Liu, Xinzhi Zhao, Chenzhen Li, Shengnan Xu, Jinli Pei, Jinming Yu, Haojun Chen, Jie Liu","doi":"10.1007/s00259-026-07905-3","DOIUrl":"https://doi.org/10.1007/s00259-026-07905-3","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the diagnostic performance of [¹⁸F]AlF-NOTA-QHY-04 PET/CT, a novel CXCR4-targeted imaging agent, in detecting primary central nervous system lymphoma (PCNSL) at initial diagnosis and suspected recurrence, in comparison with contrast-enhanced magnetic resonance imaging (CE-MRI) and [¹⁸F]FDG PET/CT.</p><p><strong>Methods: </strong>We prospectively enrolled patients with suspected PCNSL between September 2022 and December 2024. A total of 29 patients underwent both CE-MRI and [¹⁸F]AlF-NOTA-QHY-04 PET/CT, with 20 patients also receiving [¹⁸F]FDG PET/CT. Biopsy pathology served as the reference standard for newly diagnosed lesions. Recurrence was assessed using a composite reference standard based on CE-MRI, clinical follow-up, and cerebrospinal fluid (CSF) findings when available; an exploratory sensitivity analysis excluded MRI-dependent cases. Imaging parameters including the maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), and tumor-to-background ratios (TBR) were calculated. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis and compared.</p><p><strong>Results: </strong>Six treatment-naïve patients (14 lesions) and 16 patients with recurrence (16 lesions) were confirmed, along with 7 patients without recurrence. Both primary and recurrent lesions showed intense tracer uptake on [¹⁸F]AlF-NOTA-QHY-04 PET/CT, characterized by notably high TBR. In the 20-patient subgroup undergoing both PET scans, [¹⁸F]AlF-NOTA-QHY-04 demonstrated significantly lower absolute SUVmax compared to [¹⁸F]FDG (median: 2.42 vs. 11.73, P < 0.001) but a substantially higher TBR-SUVmax (median: 42.75 vs. 1.07, P < 0.001), leading to the identification of more positive lesions (14 vs. 7, P = 0.023). Relative to the composite reference standard, [¹⁸F]AlF-NOTA-QHY-04 PET/CT achieved sensitivity and accuracy (87.50% and 90.91%, respectively) comparable to CE-MRI (100% for both, P > 0.05) and significantly superior to [¹⁸F]FDG PET/CT (43.75% and 59.09%, P = 0.023). ROC analysis identified [¹⁸F]AlF-NOTA-QHY-04 SUVmax as the optimal diagnostic parameter (AUC = 0.979).</p><p><strong>Conclusion: </strong>[¹⁸F]AlF-NOTA-QHY-04 PET/CT demonstrated high tumor-to-background contrast in PCNSL, consistent with its low background brain uptake. It shows diagnostic accuracy comparable to CE-MRI and significantly superior to [¹⁸F]FDG PET/CT, demonstrating high potential as a valuable imaging tool for the diagnosis and restaging of PCNSL.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Dementias Platform UK PET/MR harmonisation and test-retest study: assessment of PET repeatability and reproducibility across the national network.","authors":"Pawel J Markiewicz,Gerard Thompson,Joanna M Wardlaw,Catriona Wimberley,Craig Ritchie,John-Paul Taylor,David Brooks,Ross Maxwell,Michael Firbank,Nigel Hoggard,Li Su,Jim Wild,Philip Hillel,Victoria Rhodes-Bradford,Laura M Parkes,John T O'Brien,Stephen F Carter,Franklin I Aigbirhio,Tim Fryer,Paul M Matthews,Paresh Malhotra,Gabrielle Grey,Will Hallett,Dilek Ocal,John C Dickson,Enrico De Vita,David L Thomas,Nick C Fox,Giorgios Krokos,Jane E Mackewn,Paul Marsden,Alexander Hammers,Karl Herholz,Frederik Barkhof,Julian C Matthews","doi":"10.1007/s00259-026-07885-4","DOIUrl":"https://doi.org/10.1007/s00259-026-07885-4","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"30 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147754631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic accuracy of radiolabelled-WBC scintigraphy in patients with antibiotic therapy.","authors":"Chiara Lauri,Giuseppe Campagna,Roberta Ottaviani,Mariano Pontico,Michela Varani,Valeria Bentivoglio,Simone Tetti,Walter Davide Vella,Miriam Lichtner,Alberto Signore","doi":"10.1007/s00259-026-07855-w","DOIUrl":"https://doi.org/10.1007/s00259-026-07855-w","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"6 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147754634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}